Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
17.50
+0.55 (3.24%)
Dec 3, 2024, 1:44 PM EST - Market open
Centessa Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 6.85 | 6.85 | - | - | - | - |
| Gross Profit | 6.85 | 6.85 | - | - | - | - |
| Selling, General & Admin | 49.42 | 53.73 | 55.2 | 43.01 | 1.14 | 0.79 |
| Research & Development | 119.09 | 124.41 | 155.08 | 96.32 | 9.3 | 4.26 |
| Operating Expenses | 168.51 | 178.14 | 210.28 | 139.33 | 10.44 | 5.05 |
| Operating Income | -161.65 | -171.28 | -210.28 | -139.33 | -10.44 | -5.05 |
| Interest Expense | -10.18 | -9.91 | -7.28 | -2.55 | -0.38 | -0.12 |
| Interest & Investment Income | 12.1 | 10.48 | 0.24 | - | - | 0.01 |
| Currency Exchange Gain (Loss) | 2.8 | 0.8 | -2.8 | -3.6 | - | - |
| Other Non Operating Income (Expenses) | 0.3 | -0.33 | -0.76 | -0.77 | 0.16 | 0.11 |
| EBT Excluding Unusual Items | -156.63 | -170.24 | -220.87 | -146.25 | -10.66 | -5.06 |
| Other Unusual Items | -1.7 | -5.9 | 3.92 | -15.08 | - | - |
| Pretax Income | -158.33 | -176.14 | -216.95 | -381.79 | -10.66 | -5.06 |
| Income Tax Expense | 2.94 | -25.06 | -0.75 | 0.11 | - | - |
| Net Income | -161.27 | -151.09 | -216.21 | -381.9 | -10.66 | -5.06 |
| Preferred Dividends & Other Adjustments | - | - | - | -0.83 | - | - |
| Net Income to Common | -161.27 | -151.09 | -216.21 | -381.07 | -10.66 | -5.06 |
| Shares Outstanding (Basic) | 106 | 96 | 93 | 75 | 15 | - |
| Shares Outstanding (Diluted) | 106 | 96 | 93 | 75 | 15 | - |
| Shares Change (YoY) | 11.08% | 2.97% | 24.26% | 401.11% | - | - |
| EPS (Basic) | -1.52 | -1.57 | -2.31 | -5.07 | -0.71 | - |
| EPS (Diluted) | -1.52 | -1.57 | -2.31 | -5.07 | -0.71 | - |
| Free Cash Flow | -130.37 | -160.51 | -201.68 | -136.34 | -10.63 | -5.83 |
| Free Cash Flow Per Share | -1.23 | -1.67 | -2.16 | -1.81 | -0.71 | - |
| Gross Margin | 100.00% | 100.00% | - | - | - | - |
| Operating Margin | -2358.86% | -2499.39% | - | - | - | - |
| Profit Margin | -2353.20% | -2204.65% | - | - | - | - |
| Free Cash Flow Margin | -1902.33% | -2342.20% | - | - | - | - |
| EBITDA | -161.3 | -170.97 | -210.15 | -139.3 | -10.43 | -5.05 |
| D&A For EBITDA | 0.35 | 0.31 | 0.13 | 0.03 | 0.01 | 0.01 |
| EBIT | -161.65 | -171.28 | -210.28 | -139.33 | -10.44 | -5.05 |
Source: S&P Capital IQ. Standard template.
Financial Sources.